1. Home
  2. NTRA vs IDXX Comparison

NTRA vs IDXX Comparison

Compare NTRA & IDXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

N/A

Current Price

$400.92

Market Cap

47.4B

Sector

Health Care

ML Signal

N/A

Logo IDEXX Laboratories Inc.

IDXX

IDEXX Laboratories Inc.

N/A

Current Price

$516.52

Market Cap

45.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NTRA
IDXX
Founded
2003
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.4B
45.4B
IPO Year
2015
1996

Fundamental Metrics

Financial Performance
Metric
NTRA
IDXX
Price
$400.92
$516.52
Analyst Decision
Strong Buy
Buy
Analyst Count
23
13
Target Price
$383.66
★ $701.33
AVG Volume (30 Days)
★ 1.7M
438.3K
Earning Date
11-05-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
0.65
★ 22.59
EPS
N/A
★ 7.74
Revenue
$210,939,000.00
★ $4,303,702,000.00
Revenue This Year
$26.17
$9.73
Revenue Next Year
$20.65
$8.86
P/E Ratio
★ N/A
$66.30
Revenue Growth
N/A
★ 10.42
52 Week Low
$169.50
$500.61
52 Week High
$437.41
$769.98

Technical Indicators

Market Signals
Indicator
NTRA
IDXX
Relative Strength Index (RSI) 61.52 45.70
Support Level $187.64 $500.61
Resistance Level N/A $581.28
Average True Range (ATR) 17.33 11.52
MACD -3.35 0.71
Stochastic Oscillator 50.04 41.38

Price Performance

Historical Comparison
NTRA
IDXX

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About IDXX IDEXX Laboratories Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.

Share on Social Networks: